A case of keratitis due to Acanthamoeba in New York, New York, and features of 10 cases.
A man in New York, New York, contracted keratitis caused by Acanthamoeba castellanii. The diagnosis was delayed because amoebae were not initially suspected as the infectious organism. The culture isolate and the amoebae in corneal sections were identified as A. castellanii by immunofluorescence using antiserum to plasma membranes of this species. With the rapid agar disk diffusion method, the amoebae were shown to e susceptible to pimaricin (0.5%) and resistant to greater than 1,000-micrograms/ml levels of paromomycin, polymyxin B-bacitracin-neomycin, acriflavine, 5-fluorocytosine, amphotericin B, gentamicin, and trimethoprim-sulfamethoxazole. The infection responded to treatment with pimaricin administered with several other drugs. This infection is the eighth case reported in the literature of acanthamoebic keratitis and emphasizes the need for clinicians to consider acanthamoebic infection in the differential diagnosis of eye infections that fail to respond to bacterial, fungal, and viral therapy.
D000328:Adult; D000368:Aged; D000656:Amoeba / Q000472:pathogenicity; D000818:Animals; D001285:Atropine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007634:Keratitis / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010866:Natamycin / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D009519:New York City; D012293:Rifampin / Q000627:therapeutic use; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use
C007419:dihydrouracil; D014498:Uracil; D001285:Atropine; D003907:Dexamethasone; D010866:Natamycin; D009355:Neomycin; D012293:Rifampin